MDNews - Lower Hudson/Bronx

November 2012

Issue link: https://viewer.e-digitaledition.com/i/90670

Contents of this Issue

Navigation

Page 15 of 27

++++++++++++++++++++++ + + ++++++++++++++++++++++ CANCER UPDATE +++ +++ Dedicating New Resources to Care for the Elusive Neuroendocrine Tumor NEUROENDOCRINE TUMORS ARE A RARE, SLOW- GROWING CANCER THAT AFFECTS FEWER THAN THREE INDIVIDUALS PER 100,000, BUT THAT DOESN'T MEAN PATIENTS FACE A BARRIER TO SPECIALIZED CARE. MONTEFIORE EINSTEIN CENTER FOR CANCER CARE IS HOME TO A 3-YEAR-OLD PROGRAM THAT GIVES PATIENTS WITH AN UNCOMMON CANCER ACCESS TO THE MOST ADVANCED TREATMENT AND CLINICAL RESEARCH. T HE E STA B LI SHMEN T O F Montefiore Einstein Center for Cancer Care's Endocrine and Neuroendocrine Tumor Program, the first of its kind in the New York metropolitan area and one of only a few in the country, comes at a time when neuroendocrine tumors have dramatically increased in incidence. Figures have more than doubled in the last 10 to 15 years, according to Steven K. Libutti, M.D., Director of Montefiore Einstein Center for Cancer Care, Vice Chair of the Department of Surgery at Montefiore Medical Center and professor of surgery and genetics at Albert Einstein College of Medicine. "Because neuroendocrine tumors tend to be rare, there aren't many therapies for treating them," says Dr. Libutti. "That creates a need for new strategies involving research and multidisciplinary care, which is best served by a focused, well-coordinated program." Dr. Libutti has assembled a team of some of the most accomplished physicians in the field. Because neuroendocrine tumors often originate in the gastroin- testinal tract, gastroenterologists are actively involved. The multidisciplinary approach also employs specialists in: + endocrinology + hepatobiliary + medical oncology 16 | Lower Hudson/Bronx MD NEWS s MDNEWS.COM + pulmonary/thoracic medicine + radiation oncology The Leading-Edge Treatment The mainstay of therapy is surgical resection, supported by two dedicated endocrine surgeons. Patients who are not candidates for resection, such as those with tumors that have metastasized to multiple areas of the liver, receive regional therapy or systemic therapy. Regional therapy includes a unique procedure called an isolated hepatic profusion, which surgically connects the liver to a heart/lung machine and bypasses blood around the liver back to the heart. "We can treat the liver with very high doses of chemotherapy, much higher than the body could ordinarily tolerate," says Dr. Libutti. "We're able to do it safely because the liver is very resilient and can tolerate higher doses, and since we're isolat- ing it to the liver, the rest of the body doesn't get exposed to those higher doses of chemo." The team also utilizes systemically administered agents, such as soma- tostatin; analogues, such as octreotide; or one of two recently approved agents that block important pathways involved in neuroendocrine tumors — sunitnib, which is a tyrosine kinasing inhibitor, and everolimus, an mTOR inhibitor. For patients with more advanced or aggressive tumors, the Center for Cancer Care also offers a variety of combination cytotoxic chemotherapies. Steven K. Libutti, M.D. Directed radiat ion therapy is another option to reduce the toxicity of the radiation. Seeking New Strategies Montefiore Einstein Center for Cancer Care has an active clinical trial program and currently has five neuroendocrine trials open or about to open: + A research-related genomics trial, aimed at getting a better understand- ing of genetic pathways involved in controlling tumors + An evaluation of the efficacy of everolimus, a drug approved for pan- creatic tumors, in treating metastatic gastrointestinal tumors + A comparison of the activity of evero- limus to everolimus plus a new agent called pasireotide in the treatment of pancreatic tumors + Two trials evaluating the safety and efficacy of a new Novartis compound called BEZ in treating pancreatic tumors The clinical trials aim to identify therapies to slow the growth of neuroen- docrine tumors and determine the safety and efficacy of new treatments. For more information about Montefiore Einstein Center for Cancer Care, visit www.montefiore.org/cancer. s

Articles in this issue

Links on this page

Archives of this issue

view archives of MDNews - Lower Hudson/Bronx - November 2012